$3.44
Value $546M
ACRS and AMGN stock compared: price, dividend, valuation and results, from SEC filings.
$3.44
Value $546M
$435.64
Value $235B
Aclaris Therapeutics (ACRS) has a market value of $546M and Amgen (AMGN) $235B. Over the last year, with dividends, ACRS moved +39.8% and AMGN +31.5%. Dividend yield: ACRS none, AMGN 2.31%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
ACRS$546M
AMGN$235B
AMGN is 430 times ACRS
Revenue, 12 months
ACRS$6.4M
AMGN$38.9B
AMGN is 6,078 times ACRS
Net income, 12 months
ACRS-$80M
AMGN$9.4B
Operating margin
ACRS-1,414.0%
AMGN32.4%
1,446.4 points apart
ROIC
ACRS-54.3%
AMGN16.2%
70.5 points apart
P/E
ACRS–
AMGN25.0
Dividend yield
ACRS0.0%
AMGN2.3%
2.3 points apart
5-year return
ACRS-75.1%
AMGN+146.3%
221.4 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
ACRS-75.1%
AMGN+146.4%
| Period | ACRSWith dividends | AMGNWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +39.8%Price +39.8% | +31.5%Price +27.2% |
| 3 years since November 20, 2023 | +266.0%+54.1% a yearPrice +266.0% | +79.2%+21.5% a yearPrice +64.2% |
| 5 years since November 19, 2021 | -75.1%-24.2% a yearPrice -75.1% | +146.3%+19.8% a yearPrice +111.4% |
| 10 years since November 21, 2016 | -87.3%-18.6% a yearPrice -87.3% | +302.7%+14.9% a yearPrice +199.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
ACRSAclaris TherapeuticsAMGNAmgen
| Price | $3.44 | $435.64 |
|---|---|---|
| Market value | $546M | $235B |
| Enterprise value (EV) | $341M | $276B |
| P/E | – | 25.0 |
| P/E, 5-year median | – | 23.0 |
| P/B | 3.3 | 16.4 |
| EV/EBIT | – | 21.9 |
| Free cash flow yield | – | 4.1% |
| Revenue, 12 months | $6.4M | $38.9B |
|---|---|---|
| Net income, 12 months | -$80M | $9.4B |
| Free cash flow, 12 months | -$75M | $9.6B |
| Earnings per share, 12 months | -$0.58 | $17.25 |
| Revenue growth, year on year | -58.2% | 10.0% |
| Revenue growth a year, past | +3.8%over 5 years | +7.6%over 5 years |
| EPS growth a year, past | – | +2.9%over 5 years |
| Gross margin | 79.2% | 70.9% |
|---|---|---|
| Operating margin | -1,414.0% | 32.4% |
| Net margin | -1,244.1% | 24.1% |
| ROIC | -54.3% | 16.2% |
| ROE | -60.5% | 87.8% |
| Cash | $205M | $13.2B |
|---|---|---|
| Total debt | $1.7M | $54.0B |
| Net debt / EBITDA | – | 2.3 |
| Interest cover | – | 4.8× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $10.08 |
| Dividend growth a year, past | – | +8.1%over 5 years |
| Buyback yield | – | – |
| Shareholder yield | – | 2.3% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Amgen ($235B) is about 430.4 times Aclaris Therapeutics ($546M), at today's prices.
Since November 21, 2016, ACRS's price moved -87.3% and AMGN's +199.3%. With dividends: ACRS -87.3% (-18.6% a year), AMGN +302.7% (+14.9% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Aclaris Therapeutics and 2.31% for Amgen. Over the last twelve months they paid – and $10.08 per share.
Over the last twelve months, the net margin was -1,244.1% for Aclaris Therapeutics and 24.1% for Amgen, and the operating margin -1,414.0% and 32.4%. Revenue was $6.4M and $38.9B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.